Financial Performance - The company's revenue for Q1 2023 was CNY 342,674,231.37, representing a 10.65% increase compared to CNY 309,689,607.34 in the same period last year[4] - Net profit attributable to shareholders was CNY 32,280,888.61, up 13.54% from CNY 28,430,474.85 year-on-year[4] - Basic earnings per share increased to CNY 0.25, a 13.64% rise from CNY 0.22 in the same period last year[4] - Operating profit for Q1 2023 was ¥37,358,875.98, up from ¥32,901,125.16 in the same period last year, reflecting a growth of 13.3%[16] - Net profit attributable to the parent company was ¥32,280,888.61, representing a 13.0% increase from ¥28,430,474.85 in Q1 2022[16] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to CNY 3,622,671.66, a 107.64% increase from a negative CNY 47,420,776.27 in the previous year[4] - Cash and cash equivalents increased by 296% to CNY 1,062,307,389.39, primarily due to the receipt of IPO funds[9] - Cash flow from operating activities generated a net amount of ¥3,622,671.66, a significant recovery from a net outflow of ¥47,420,776.27 in the previous year[20] - The company reported a total cash inflow from financing activities of ¥840,697,716.98, with no cash inflow recorded in the same period last year[20] Assets and Equity - Total assets increased by 85.03% to CNY 1,883,545,722.66 from CNY 1,017,942,306.12 at the end of the previous year[4] - Shareholders' equity attributable to the parent company rose by 158.24% to CNY 1,400,375,487.92 from CNY 542,280,126.94[4] - Total assets as of March 31, 2023, reached CNY 1,883,545,722.66, up from CNY 1,017,942,306.12 at the beginning of the year, indicating significant growth[14] - The company's equity attributable to shareholders rose to CNY 1,400,375,487.92 from CNY 542,280,126.94, reflecting a growth of approximately 158%[15] Investment and Expenses - The company reported a 2300% increase in cash received from investment income, totaling CNY 12,185,850.52, attributed to the maturity of cash management products[9] - Operating costs for Q1 2023 were ¥305,463,922.16, an increase of 10.7% from ¥275,858,010.64 in Q1 2022[16] - Research and development expenses rose to ¥10,593,026.01, up from ¥9,060,661.75 in the previous year, reflecting a commitment to innovation[16] Shareholder Information - The company reported a total of 103,012,300 shares held by the largest shareholder, accounting for 79.77% of total shares[11] - The total number of shareholders at the end of the reporting period was not specified, but the top ten shareholders hold a significant portion of the company[11] Other Information - The company has no non-recurring profit and loss items that meet the definition of non-recurring profit and loss[6] - The company has not disclosed any new product developments or market expansion strategies in the current report[12] - There are no indications of mergers or acquisitions in the recent financial disclosures[12] - Accounts receivable decreased slightly to CNY 39,290,375.86 from CNY 40,666,909.25, indicating a reduction of about 3.4%[14] - Inventory increased to CNY 214,522,819.61 from CNY 197,079,082.32, marking an increase of approximately 8.9%[14]
登康口腔(001328) - 2023 Q1 - 季度财报